Erratum to ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density(Mol. Med (2013) 19 334-45 10.2119/molmed.2013.00122);ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density

Molecular Medicine

Volumn 19, Issue 1, 2013, Pages 334-345

  Dahan, Albert ^a   Dunne, Ann ^b   Swartjes, Maarten ^a   Proto, Paolo L ^a   Heij, Lara ^a   Vogels, Oscar ^c   van Velzen, Monique ^a   Sarton, Elise ^a   Niesters, Marieke ^a   Tannemaat, Martijn R ^a   Cerami, Anthony ^a,b   Brines, Michael ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ARAIM PHARMACEUTICALS   (United States)

^c ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARA 290; PEPTIDE; PLACEBO; UNCLASSIFIED DRUG;

ADVERSE OUTCOME; AREA UNDER THE CURVE; ARTICLE; BRIEF PAIN INVENTORY; CLINICAL ARTICLE; CLINICAL EVALUATION; COLD PAIN THRESHOLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEAL SMALL NERVE FIBER DENSITY; CUTANEOUS PARAMETERS; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; EXERCISE; FEMALE; HEAT PAIN THRESHOLD; HUMAN; HUMAN TISSUE; INTRAEPIDERMAL NERVE FIBER DENSITY; IRRITABILITY; MALE; MECHANICAL DETECTION THRESHOLD; MECHANICAL PAIN THRESHOLD; NERVOUS SYSTEM INJURY; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PRESSURE PAIN THRESHOLD; PRIORITY JOURNAL; QUALITY OF LIFE; RETINA EDEMA; RETINAL THICKNESS; SARCOIDOSIS; SCORING SYSTEM; SIDE EFFECT; SKIN SENSITIVITY; SMALL NERVE FIBER LOSS AND DAMAGE; TEMPERATURE SENSITIVITY; THERMAL SENSORY LIMEN; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS;

CORNEA; DRUG ADMINISTRATION SCHEDULE; ERYTHROMELALGIA; EXERCISE TEST; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MICROSCOPY, CONFOCAL; MIDDLE AGED; NERVE FIBERS; OLIGOPEPTIDES; SARCOIDOSIS;

EID: 84887575038     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2013.00122.erratum     Document Type: Erratum

References (44)

1. Iannuzzi MC, Rybicki BA, Teirstein AS. (2007) Sarcoidosis. N. Engl. J. Med. 357:2153-65
2. Chen ES, Moller DR. (2011) Sarcoidosis: scientific progress and clinical challenges. Nat. Rev. Rheumatol. 7:457-67.
3. Baughman RP, et al. (2011) Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG Task Force. Sarcoidosis Vasc. Diffuse Lung Dis. 28:56-64.
4. Bakkers M, et al. (2010) Pain and autonomic dysfunction in patients with sarcoidosis and small fibre neuropathy. J. Neurol. 257:2086-90
5. Heij L, Dahan A, Hoitsma E. (2012) Sarcoidosis and pain caused by small-fiber neuropathy. Pain Res. Treat. 2012:256024.
6. Hoitsma E, et al. (2002) Small fibre neuropathy in sarcoidosis. Lancet. 359:2085-6.
7. Judson MA. (2011) Small fiber neuropathy in sarcoidosis: something beneath the surface. Respir. Med. 105:1-2.
8. Tavee J, Culver D. (2011) Sarcoidosis and small-fiber neuropathy. Curr. Pain Headache Rep. 15:201-6
9. Bakkers M, et al. (2009) Intraepidermal nerve fiber density and its application in sarcoidosis. Neurology. 73:1142-8.
10. Hoitsma E, et al. (2003) Impact of pain in a Dutch sarcoidosis patient population. Sarcoidosis Vasc. Diffuse Lung Dis. 20:33-9.
11. Uceyler N, et al. (2010) Elevated proinflammatory cytokine expression in affected skin in small fiber neuropathy. Neurology. 74:1806-13.
12. Tavee J, Zhou L. (2009) Small fiber neuropathy: a burning problem. Cleve. Clin. J. Med. 76:297-305.
13. Brines M, et al. (2008) Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc. Natl. Acad. Sci. U. S. A. 105:10925-30.
14. Brines M, Cerami A. (2012) The receptor that tames the innate immune response. Mol. Med. 18:486-96.
15. Swartjes M, et al. (2011) ARA290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain: an experimental study in rats and beta-common receptor knockout mice. Anesthesiology. 115:1084-92.
16. Pulman KG, et al. (2013) The erythropoietin-derived peptide ARA290 reverses mechanical allodynia in the neuritis model. Neuroscience. 233:174-83.
17. Bianchi R, et al. (2006) Protective effect of erythropoietin and its carbamylated derivative in experimental Cisplatin peripheral neurotoxicity. Clin. Cancer Res. 12:2607-12.
18. Bianchi R, et al. (2004) Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proc. Natl. Acad. Sci. U. S. A. 101:823-8.
19. Niesters M, et al. (2013) The erythropoietin-analogue ARA 290 for treatment of sarcoidosis-induced chronic neuropathic pain. Exp. Opin. Orphan Drugs. 1:77-87.
20. Heij L, et al. (2012) Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Mol. Med. 18:1430-6.
21. Hoitsma E, De Vries J, Drent M. (2011) The small fiber neuropathy screening list: construction and cross-validation in sarcoidosis. Respir. Med. 105:95-100.
22. Marcellis RG, et al. (2011) Exercise capacity, muscle strength and fatigue in sarcoidosis. Eur. Respir. J. 38:628-34.
23. Costabel U, Hunninghake GW. (1999) ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis Statement Committee. American Thoracic Society. European Respiratory Society. World Association for Sarcoidosis and Other Granulomatous Disorders. Eur. Respir. J. 14:735-7.
24. Rolke R, et al. (2006) Quantitative sensory testing: a comprehensive protocol for clinical trials. Eur. J. Pain. 10:77-88.
25. Lauria G, et al. (2010) European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur. J. Neurol. 17:903-12, e44-9.
26. Lauria G, et al. (2010) Intraepidermal nerve fiber density at the distal leg: a worldwide normative reference study. J. Peripher. Nerv. Syst. 15:202-7.
27. Umapathi T, et al. (2006) Determinants of epidermal nerve fiber density in normal individuals. Muscle Nerve. 33:742-6.
28. Tavakoli M, Malik RA. (2011) Corneal confocal microscopy: a novel non-invasive technique to quantify small fibre pathology in peripheral neuropathies. J. Vis. Exp. January 3:pii: 2194.
29. Schneider CA, Rasband WS, Eliceiri KW. (2012) NIH Image to ImageJ: 25 years of image analysis. Nat. Methods. 9:671-5.
30. Brines M, et al. (2013) Corneal nerve quantification predicts the severity of symptoms in sarcoidosis patients with painful neuropathy. Technology. 1:1-7.
31. ATS statement. (2002) Guidelines for the six-minute walk test. Am. J. Respir. Crit. Care Med. 166:111-7.
32. Troosters T, Gosselink R, Decramer M. (1999) Six minute walking distance in healthy elderly subjects. Eur. Respir. J. 14:270-4.
33. Quattrini C, et al. (2007) Surrogate markers of small fiber damage in human diabetic neuropathy. Diabetes. 56:2148-54.
34. Boyd AL, et al. (2010) Topiramate improves neurovascular function, epidermal nerve fiber morphology, and metabolism in patients with type 2 diabetes mellitus. Diabetes Metab. Syndr. Obes. 3:431-7.
35. Polydefkis M, et al. (2004) The time course of epidermal nerve fibre regeneration: studies in normal controls and in people with diabetes, with and without neuropathy. Brain. 127:1606-15.
36. Gibbons CH, Wang N, Freeman R. (2010) Capsaicin induces degeneration of cutaneous autonomic nerve fibers. Ann. Neurol. 68:888-98.
37. Tanelian DL, Monroe S. (1995) Altered thermal responsiveness during regeneration of corneal cold fibers. J. Neurophysiol. 73:1568-73.
38. Sorensen L, Molyneaux L, Yue DK. (2006) The level of small nerve fiber dysfunction does not predict pain in diabetic neuropathy: a study using quantitative sensory testing. Clin. J. Pain. 22:261-5.
39. Rukwied R, et al. (2010) Nerve growth factor-evoked nociceptor sensitization in pig skin in vivo. J. Neurosci. Res. 88:2066-72.
40. Apfel SC, et al. (2000) Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: a randomized controlled trial. rhNGF Clinical Investigator Group. JAMA. 284:2215-21.
41. Baughman RP, Sparkman BK, Lower EE. (2007) Six-minute walk test and health status assessment in sarcoidosis. Chest. 132:207-13.
42. Gremeaux V, et al. (2011) Determining the minimal clinically important difference for the six-minute walk test and the 200-meter fast-walk test during cardiac rehabilitation program in coronary artery disease patients after acute coronary syndrome. Arch. Phys. Med. Rehabil. 92:611-9.
43. Eckstein C, et al. (2012) Detection of clinical and subclinical retinal abnormalities in neurosarcoidosis with optical coherence tomography. J. Neurol. 259:1390-8.
44. Papanas N, Vinik AI, Ziegler D. (2011) Neuropathy in prediabetes: does the clock start ticking early? Nat. Rev. Endocrinol. 7:682-90.